ADVANTAN OINTMENT
METHYLPREDNISOLONE ACEPONATE
What it does
Aceponate is a topical medication used to reduce inflammation and relieve itching.
Commonly used for: skin inflammation (dermatitis), eczema, allergic reactions, psoriasis
Read more in plain English ↓Plain-language summary for general understanding - not medical advice. Always follow your pharmacist/doctor.
Ask about this medicine
Answers come only from this medicine's registration record, BNF monograph and interaction data - not medical advice.
Hard to find? We help patients in Kenya source rare medicines. We don't sell or dispense medicines - licensed pharmacies do.
Source this medicineRegistration & product details
Source: Pharmacy and Poisons Board · fetched 2026-01-28 21:31:58 · updated 2026-07-20 11:06:08
Drug Interactions
53Pharmacodynamic Warnings
Methylprednisolone appears in TABLE 17: Drugs that reduce serum potassium
Severe (1)
Mifamurtide - decreases efficacy
Corticosteroidsarepredictedtodecreasetheefficacyof mifamurtide.Avoid.rTheoretical
Moderate (32)
Corticosteroids - increases exposure
Dronedarone is predicted to increase the exposure to corticosteroids (methylprednisolone). Monitor and adjust dose.
Corticosteroids - increases concentration
Miconazole is predicted to increase the concentration of corticosteroids (methylprednisolone). Monitor and adjust dose.
Corticosteroids - increases exposure
Antifungals, azoles (fluconazole, isavuconazole, posaconazole) are predicted to increase the exposure to corticosteroids (methylprednisolone). Monitor and adjust dose.
Corticosteroids - decreases exposure
Cenobamate is predicted to decrease the exposure to corticosteroids (fluticasone). Adjust dose.
Corticosteroids - decreases efficacy
Mifepristone is predicted to decrease the efficacy of corticosteroids. Use with caution and adjust dose.
Unknown (20)
Aspirin - decreases concentration
Corticosteroids are predicted to decrease the concentration of aspirin (high-dose) and aspirin (high-dose) increases the risk of gastrointestinal bleeding when given with corticosteroids.
Choline Salicylate - decreases concentration
Corticosteroids are predicted to decrease the concentration of cholinesalicylate. Ciclesonide → see corticosteroids Ciclosporin → see TABLE 2 p. 1517 (nephrotoxicity), TABLE 16 p. 1521 (increased seru
Corticosteroids - increases exposure
Cobicistat is predicted to increase the exposure to corticosteroids (beclometasone) (risk with beclometasone is likely to be lower than with other corticosteroids).
Corticosteroids - increases risk of gastrointestinal perforation
Erlotinib is predicted to increase the risk of gastrointestinal perforation when given with corticosteroids.
Corticosteroids - increases exposure
Idelalisib is predicted to increase the exposure to corticosteroids (betamethasone, budesonide, ciclesonide, deflazacort, dexamethasone, fludrocortisone, fluticasone, hydrocortisone, methylprednisolon
Data from BNF 85 (British National Formulary). This is not a substitute for professional medical advice. Matched via: class
About aceponate
Aceponate is a topical medication used to reduce inflammation and relieve itching.
What it treats
- skin inflammation (dermatitis)
- eczema
- allergic reactions
- psoriasis
How it works
It helps to reduce swelling, redness, and itching by calming the skin's immune response.
Who it's for
It is suitable for adults and children with skin conditions that require anti-inflammatory treatment.
AI-assisted summary grounded in BNF data - general information only, not medical advice. Always confirm with your pharmacist or doctor.
About methylprednisolone
Methylprednisolone is a corticosteroid used to reduce inflammation and suppress the immune system.
What it treats
- allergic reactions
- asthma
- arthritis (joint inflammation)
- skin conditions
- autoimmune diseases
How it works
It works by decreasing inflammation and suppressing the activity of the immune system.
Who it's for
This medication is for people dealing with severe allergies, breathing problems, or certain autoimmune conditions.
Drug class
Corticosteroids
Cautions
- • Be careful if you are taking drugs that lower potassium levels in your blood.
AI-assisted summary grounded in BNF data - general information only, not medical advice. Always confirm with your pharmacist or doctor.
Clinical monograph: aceponate
Aceponate is a topical corticosteroid used primarily for its anti-inflammatory and immunosuppressive properties. It is effective in managing various dermatological conditions such as eczema, psoriasis, and dermatitis. Aceponate has a lower potency compared to other corticosteroids, making it suitable for use on sensitive skin areas, including the face and intertriginous regions.
Indications
- Atopic dermatitis
- Contact dermatitis
- Seborrheic dermatitis
- Psoriasis
- Nummular eczema
- Lichen planus
Dosage
Children: Refer to the specific product monograph for dosing instructions, as dosage can vary based on the formulation and the condition being treated.
Adults: Refer to the specific product monograph for dosing instructions, as dosage can vary based on the formulation and the condition being treated.
Mechanism of action
Aceponate exerts its effects by binding to glucocorticoid receptors in target tissues, leading to the modulation of gene expression. This results in the inhibition of pro-inflammatory cytokine production, reduction of inflammatory cell infiltration, and suppression of local immune responses. The drug's action ultimately leads to decreased redness, swelling, and itching associated with inflammatory skin conditions.
Pharmacodynamics
As a topical corticosteroid, aceponate reduces inflammation through the inhibition of phospholipase A2 and the subsequent decrease in the production of arachidonic acid and its metabolites, including prostaglandins and leukotrienes. This anti-inflammatory action is complemented by its ability to induce vasoconstriction in the dermal blood vessels, contributing to its efficacy in reducing both erythema and edema.
Pharmacokinetics
Aceponate is absorbed through the skin and metabolized in the liver, where it is converted into its active form. The systemic absorption of topical corticosteroids like aceponate is relatively low, especially when applied to intact skin, which minimizes potential systemic side effects. The onset of action is typically within hours, with effects persisting for several hours after application.
Contra-indications
- Hypersensitivity to aceponate or any of its components
- Active skin infections at the site of application
Adverse effects
- Local skin irritation
- Burning sensation
- Itching
- Dry skin
- Skin atrophy with prolonged use
Interactions
- Avoid concomitant use with other topical corticosteroids to prevent cumulative effects
- Caution when used with products containing similar active ingredients
Precautions
- Use with caution in patients with a history of skin disorders
- Avoid application to large areas of the body or in conjunction with occlusive dressings unless directed by a healthcare provider
- Monitor for signs of systemic absorption, especially in young children
Pregnancy
Safety during pregnancy has not been established. Use only if clearly needed and the benefits outweigh the risks.
Breast-feeding
It is unknown if aceponate is excreted in human milk. Caution is advised when administered to nursing mothers.
Storage
Store at room temperature, away from direct sunlight and moisture. Keep out of reach of children.
Formulations
- Topical cream
- Topical ointment
- Topical lotion
AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.
Clinical monograph: Methylprednisolone
BNF-referencedMethylprednisolone is a synthetic glucocorticoid corticosteroid with anti-inflammatory and immunosuppressive properties. It is primarily used to treat a variety of conditions that involve inflammation or overactive immune responses. The drug is effective in managing conditions such as allergies, asthma, autoimmune diseases, and certain cancers. Its therapeutic effects are attributed to its ability to modulate gene expression and inflammatory processes.
Indications
- Suppression of inflammatory and allergic disorders
- Cerebral oedema associated with malignancy
- Management of graft rejection reactions
- Treatment of autoimmune diseases
- Severe allergic reactions
Dosage
Children: For paediatric dosing, refer to the BNF for Children for specific guidance.
Adults: Initially 10-500 mg by intravenous infusion, or 2-40 mg orally daily, depending on the condition being treated.
Mechanism of action
Methylprednisolone exerts its effects primarily through binding to the glucocorticoid receptor, leading to decreased vasodilation and permeability of capillaries, as well as suppression of leukocyte migration to sites of inflammation. It inhibits phospholipase A2, reducing the formation of arachidonic acid derivatives, and inhibits inflammatory transcription factors such as NF-kappa B. This results in a net anti-inflammatory effect, promoting the expression of anti-inflammatory genes like interleukin-10, while higher doses can impart immunosuppressive effects.
Pharmacodynamics
As a glucocorticoid, methylprednisolone influences various physiological processes, including the modulation of the immune response and inflammation. It has a wide therapeutic window, allowing for flexibility in dosing. Long-term use can lead to suppression of the hypothalamic-pituitary-adrenal axis, increasing the risk of infections and other side effects associated with corticosteroid therapy.
Pharmacokinetics
Methylprednisolone is well absorbed from the gastrointestinal tract, with peak plasma concentrations occurring within one to two hours after oral administration. It has a half-life of approximately 18 to 36 hours, with its effects lasting longer than its plasma concentration due to its mechanism of action. The drug is primarily metabolized in the liver and excreted in the urine. It binds significantly to plasma proteins, which affects its distribution in the body.
Contra-indications
- Systemic fungal infections
- Hypersensitivity to methylprednisolone or any component of the formulation
- Live vaccines in patients receiving immunosuppressive doses
- Untreated bacterial infections
Adverse effects
- Increased susceptibility to infections
- Gastrointestinal disturbances
- Elevated blood glucose levels
- Cushing's syndrome
- Fluid retention
- Hypertension
- Osteoporosis
- Mood changes and psychiatric effects
Interactions
- Dronedarone increases exposure to methylprednisolone
- Miconazole increases concentration of methylprednisolone
- Azole antifungals increase exposure to methylprednisolone
- Crizotinib increases exposure to methylprednisolone
- Imatinib increases exposure to methylprednisolone
- Letermovir increases exposure to methylprednisolone
- Lumacaftor decreases exposure to methylprednisolone
- Mitotane decreases exposure to methylprednisolone
- Monoclonal antibodies decrease exposure to methylprednisolone
Precautions
- Use with caution in patients with a history of peptic ulcer disease
- Monitor for signs of infection and elevated blood glucose levels
- Consider dose adjustments in patients with renal or hepatic impairment
- Gradual withdrawal recommended to avoid adrenal insufficiency
Pregnancy
Use during pregnancy only if the potential benefit justifies the potential risk to the fetus. Caution is advised.
Breast-feeding
Methylprednisolone is excreted in breast milk. Caution should be exercised when administering to a nursing mother.
Storage
Store in a cool, dry place, protected from light. Keep out of reach of children.
Formulations
- Oral tablets
- Oral suspension
- Solution for injection
- Modified-release tablets
AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.
Molecular reference: Methylprednisolone
PubChem CID 6741Molecular formula: C22H30O5
Mechanism of action
The short term effects of corticosteroids are decreased vasodilation and permeability of capillaries, as well as decreased leukocyte migration to sites of inflammation. Corticosteroids binding to the glucocorticoid receptor mediates changes in gene expression that lead to multiple downstream effects over hours to days. Glucocorticoids inhibit neutrophil apoptosis and demargination; they inhibit phospholipase A2, which decreases the formation of arachidonic acid derivatives; they inhibit NF-Kappa B and other inflammatory transcription factors; they promote anti-inflammatory genes like interleukin-10. Lower doses of corticosteroids provide an anti-inflammatory effect, while higher doses are immunosuppressive. High doses of glucocorticoids for an extended period bind to the mineralocorticoid receptor, raising sodium levels and decreasing potassium levels. Glucocorticoids are capable of suppressing the inflammatory process through numerous pathways. They interact with specific intracellular receptor proteins in target tissues to alter the expression of corticosteroid-responsive genes. Glucocorticoid-specific receptors in the cell cytoplasm bind with steroid ligands to form hormone-receptor complexes that eventually translocate to the cell nucleus. There these complexes bind to specific DNA sequences and alter their expression. The complexes may induce the transcription of mRNA leading to synthesis of new proteins. Such proteins include lipocortin, a protein known to inhibit PLA2a and thereby block the synthesis of prostaglandins, leukotrienes, and PAF. Glucocorticoids also inhibit the production of other mediators including AA metabolites such as COX, cytokines, the interleukins, adhesion molecules, and enzymes such as collagenase. /Glucocorticoids/
Pharmacodynamics
Corticosteroids bind to the glucocorticoid receptor, inhibiting pro-inflammatory signals, and promoting anti-inflammatory signals. Corticosteroids have a wide therapeutic window as patients may require doses that are multiples of what the body naturally produces. Patients taking corticosteroids should be counselled regarding the risk of hypothalamic-pituitary-adrenal axis suppression and increased susceptibility to infections.
Biological pathways
Source: PubChem (NCBI) · pathways from PathBank, Reactome, WikiPathways & PharmGKB.
This drug in other countries
The same active ingredient registered across other registries we cover - including different brands.
- DEBO-METHYL-40 40MG/ML STERILE AQUEOUS SUSPENSION
- DEPO-MEDROL 40MG/ML AQUEOUS SUSPENSION
- DEPO-MEDROL 40MG/ML AQUEOUS SUSPENSION
- MEDROL 4MG TABLET
- MEDROL 4MG TABLET
- NEO-DROL 40MG/VIAL POWDER FOR INJECTION